Compare BANL & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANL | SLGL |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | Malaysia | Israel |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 117.8M |
| IPO Year | 2023 | 2018 |
| Metric | BANL | SLGL |
|---|---|---|
| Price | $0.44 | $39.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 27.8K | 15.3K |
| Earning Date | 09-04-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $580,456,800.00 | $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 11.38 | ★ 62.04 |
| 52 Week Low | $0.40 | $4.02 |
| 52 Week High | $1.30 | $52.26 |
| Indicator | BANL | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 50.95 |
| Support Level | $0.44 | $38.37 |
| Resistance Level | $0.46 | $43.90 |
| Average True Range (ATR) | 0.02 | 4.01 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 61.73 | 41.27 |
CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.